Navigation Links
Artemis Health Hires Richard Rava, Ph.D., as Senior Vice President of Research and Development
Date:2/9/2009

MENLO PARK, Calif., Feb. 9 /PRNewswire/ -- Artemis Health Inc., a privately-held company dedicated to the development of non-invasive prenatal diagnostic tests, today announced that Richard Rava, Ph.D., has joined Artemis Health in the newly created position of senior vice president of research and development.

"Rich's depth and breadth of research, development and manufacturing experience, together with his proven track record in commercializing genetic analysis tools, makes him uniquely suited to lead our efforts to bring non-invasive prenatal diagnostic tests to the market," said Lissa Goldenstein, president and chief executive officer of Artemis Health.

Dr. Rava brings more than 20 years of research, development and operational expertise in molecular and genetic analysis for commercial assays and instrumentation. He comes to Artemis after 16 years at Affymetrix where he was a scientific co-founder and most recently senior vice president of research and development. During his tenure, Dr. Rava led the research, development and manufacturing scale-up of the Affymetrix' GeneChip(R) technology. He was responsible for the delivery of multiple products involving complex assays, microarrays, instrumentation and software that applied scientific technology to meet the needs of the gene expression, genetics research and clinical markets.

Prior to co-founding Affymetrix, Dr. Rava served as a senior scientist at Affymax Research Institute. From 1990 through 1992, he served as principal research scientist at the George R. Harrison Spectroscopy Laboratory, Massachusetts Institute of Technology (MIT). During that time, he was also the research coordinator for the National Institute of Health Laser Biomedical Research Center at MIT. Dr. Rava has published over 60 papers in peer-reviewed scientific publications and is an author on over 30 issued U.S. patents. He received
'/>"/>

SOURCE Artemis Health Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Exelixis Sells 80% Stake in Artemis to Taconic
2. Artemis Health Licenses Prenatal Cell-Free DNA Analysis Technology from Stanford University
3. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
4. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
5. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
6. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
7. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
8. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
9. InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom
10. Apria Healthcare Chooses Masimo SET Pulse Oximetry for Use in the Companys Home Health Care Business
11. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... US-Australian drug discovery company, Novogen Limited (ASX: ... committed to progressing its ground-breaking technology platforms to Phase ... ensure the Company delivers the best value for shareholders. ... , said the Company currently had an extensive program ... programs and academic partnerships and initiatives, and he was ...
(Date:7/29/2015)... July 29, 2015  HealthSouth Corporation (NYSE: ... providers of post-acute healthcare services, offering both facility-based ... of operations for the second quarter ended June 30, ... characterized by strong volume growth in both segments ... said Jay Grinney, President and Chief Executive Officer ...
(Date:7/29/2015)... , July 29, 2015 ... announced the addition of the "Global Biosimilars ... offering. The Global Biosimilars Market, 2015 ... the rapidly growing biosimilars market. With the blockbuster ... to minimize costs, biosimilars are being viewed as ...
(Date:7/29/2015)... YORK , July 29, 2015  Therapath ... testing, announces increased partnerships with VA and Military ... Epidermal Nerve Fiber Density (ENFD) and Sweat Gland ... small fiber neuropathy ( https://therapath.com/skin ). ... Nerve Fiber Density (ENFD) on punch skin biopsy ...
Breaking Biology Technology:Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15HealthSouth Reports Results for Second Quarter 2015 16HealthSouth Reports Results for Second Quarter 2015 17HealthSouth Reports Results for Second Quarter 2015 18HealthSouth Reports Results for Second Quarter 2015 19HealthSouth Reports Results for Second Quarter 2015 20HealthSouth Reports Results for Second Quarter 2015 21HealthSouth Reports Results for Second Quarter 2015 22HealthSouth Reports Results for Second Quarter 2015 23HealthSouth Reports Results for Second Quarter 2015 24HealthSouth Reports Results for Second Quarter 2015 25HealthSouth Reports Results for Second Quarter 2015 26HealthSouth Reports Results for Second Quarter 2015 27
... VANCOUVER, May 11 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ... final survival data from a randomized Phase 2 ... docetaxel alone as first-line chemotherapy in patients with ... an oral presentation at the American Society of ...
... May 11 Dalton Pharma Services and ProCitius Research ... with contract chemistry services of ... maintain their discovery and development output in an era ... of "offshore" contract research organizations ...
... Barnard, has been awarded the International Union of Pure ... Computational Physics. , The award acknowledges Dr Barnard as ... the structures, shapes and crystal structures of materials at ... Melbourne Institute of Technology (RMIT) University in 2001 ...
Cached Biology Technology:OncoGenex Pharmaceuticals' Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting 2OncoGenex Pharmaceuticals' Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting 3Dalton Pharma Services and ProCitius Announce a Strategic Alliance to Provide Contract Chemistry Services 2Dalton Pharma Services and ProCitius Announce a Strategic Alliance to Provide Contract Chemistry Services 3Big prize for 'small science' physicist 2
(Date:7/2/2015)... 2015 Research and Markets( ... "Next Generation Biometrics Market by Application, Technology, Function & ... their offering. The next generation biometrics market ... a CAGR of 17.9% between 2015 and 2020 ... the market. Safran SA ( France ...
(Date:6/30/2015)... , June 30, 2015 Genisphere ... as CEO to help further develop Genisphere,s therapeutics capabilities ... partnering experience, having spent much of the last 25 ... Amgen, Baxter Bioscience, and Johnson & Johnson. Tom started ... Technology and Biotech Corporate Finance. He graduated from Dartmouth ...
(Date:6/25/2015)... , June 25, 2015 ... Sensors Market by Type (Swipe & Area), Technology, Material ... Government, Healthcare, Commercial Security & Others) & Geography ... by marketsandmarkets, the said market is expected to ... of 17.1%. Browse 76 market ...
Breaking Biology News(10 mins):Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4
... For a new study in the Journal of Animal ... the immune system of adult horses. According to the researchers, ... been evaluated in other species but not extensively in horses. ... of Kentucky, said the amount of selenium in soil and ...
... can be used to generate an "out-of-body experience," according ... Science , a journal of the Association for Psychological ... for people with self-perception disorders, including anorexia. The ... in the UK and Lukas Heydrich of the Swiss ...
... found in humans originated in cattle at least 40 years ago, ... livestock were the original source of an MRSA strain which is ... more than 40 strains of a bacterium -- called Staphylococcus ... into MRSA. At least two genetic subtypes of the bacterium, ...
Cached Biology News:Researchers study selenium's effects on horses 2Visualized heartbeat can trigger 'out-of-body experience' 2Cattle can be a source of MRSA in people, scientists find 2
Porcine Coronary Artery Endothelial Cells (PCAEC) (>500,000 cells)...
... of your ValveBank system! Program your valve ... running Windows 98, 2000, XP using graphic 'click-and-drag' ... print out program listings, then download your programs ... EasyCode is used for programming before -- not ...
... Monoclonal Anti-β-Tubulin IV Recognizes ... C-terminal sequence of β-tubulin isotype ... tubulin isotypes is observed. ascites ... the C-terminal sequence of β-tubulin ...
Sulfadimethoxine (CH-2027)...
Biology Products: